Quest Diagnostics stock rises 3.01% as Haystack MRD wins New York approval, Quest Diagnostics announces

Quest Diagnostics stock rises 3.01% as Haystack MRD wins New York approval, Quest Diagnostics announces
Quest Diagnostics jumps 3.01% today

Quest Diagnostics achieved a milestone with the approval of Haystack MRD by New York State.

With this approval, Haystack MRD is now available in all 50 U.S. states. Quest Diagnostics said this will help expand access to advanced cancer monitoring.

Highlights

  • DGX shows a persistent bullish structure, trading above key moving averages with strong buy signals from several momentum indicators.
  • The stock rallied 3.01% today and gained 4.16% over the past week, now testing the upper end of its weekly trading range.
  • Expected range for the coming week is $203.00 to $208.50, with immediate support at $197.00–$198.00 and high probability of upside continuation unless price breaks below support.

Bullish structure holds as price stays above key supports

DGX is trading firmly above its MA-20 ($197.63), MA-50 ($194.89), and MA-200 ($189.74), highlighting a persistent bullish structure across all primary timeframes. The Ichimoku Kijun on D1 stands at $196.98, placing it below the current price and establishing this level as immediate support.

Mixed momentum as strong intraday gains meet hesitant trend signals

Momentum on D1 is strong, as MACD signals a strong buy while ADX remains subdued at 13.96, pointing to a trend but with limited conviction. RSI is neutral-to-bullish at 50.52, and Stoch RSI gives a strong buy signal, although BBP indicates slight seller dominance with oversold classification. CCI and the Awesome Oscillator remain neutral and add little directional bias. In today's session, the stock rallied 3.01%, pointing to renewed buyers’ interest. Over the last week, DGX has advanced $8.11 (4.16%) from a previous weekly close of $195.00. The price now sits at the very top of this week's range, with weekly volatility standing at 2.55%. This marks a decisive recovery from last week's lows and a test of upper resistance.

Upside bias persists with consolidation expected unless support breaks

For the coming week, the expected price range is $203.00 to $208.50, tightly anchored near the current price and well within the recent yearly high of $213.50 and above the 52-week low of $164.65. Based on W1 signals (RSI, ADX, MACD, MA-50), there is a very high probability (more than 80%) of further upside, with a downtrend scenario much less likely. Baseline scenario: DGX consolidates between immediate support ($197.00–$198.00) and resistance ($205.80–$208.50). Bullish scenario: a breakout above near-term resistance opens the path towards retesting yearly highs. Bearish scenario: sustained weakness below $197 would challenge key support at $194.90.

Earlier, analysts noted that Quest Diagnostics was experiencing short- and medium-term bearish pressure while consolidating above longer-term support levels. Building on this, current market conditions highlight the need for traders to monitor potential upside momentum should DGX stabilize above its recent support zone.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.